ARS Pharmaceuticals, Inc. SPRY Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s total operating expenses?
- ARS Pharmaceuticals, Inc. (SPRY) reported total operating expenses of $82.83M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s total operating expenses changed year-over-year?
- ARS Pharmaceuticals, Inc.'s total operating expenses increased by 83.4% year-over-year, from $45.15M to $82.83M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s total operating expenses?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s total operating expenses has grown at a 92.7% compound annual growth rate (CAGR), from $36.83M to $263.73M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.